MeSH D012128 - respiratory distress syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Methylprednisolone | Methylprednisolone |  | 2006-10-27 |  |  |
| Novast Laboratories | Methylprednisolone | Methylprednisolone |  | 2019-01-09 |  |  |
| GSK | Epoprostenol | Flolan |  | 1995-09-20 |  |  |
| Sandoz | Methylprednisolone | Methylprednisolone |  | 1997-10-31 |  |  |
| Organon | Methylprednisolone | Methylprednisolone |  | 1982-06-25 |  |  |
| Pfizer | Methylprednisolone | Depo-medrol |  | 1982-01-01 |  |  |
| Methylprednisolone | Medrol |  | 1982-01-01 | $339 M | Y2023 | |
| Rising Pharmaceuticals | Acetylcysteine | Acetylcysteine |  | 2015-03-24 |  |  |
| Zydus Therapeutics | Acetylcysteine | Acetylcysteine |  | 2018-07-20 |  |  |
| Methylprednisolone | Methylprednisolone |  | 2018-04-23 |  |  | |
| Sun Pharmaceutical Industries | Epoprostenol | Epoprostenol |  | 2021-01-15 |  |  |
| Hospira | Methylprednisolone | A-methapred |  | 2005-12-20 |  |  |
| Acetylcysteine | Acetylcysteine |  | 1989-05-01 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
88%22/25
Phase 2
54%53/98
Phase 3
28%25/88
Approved: 3Overall Success rate: 14%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use